PRESENTATION

Paulo Rodrigues-Santos is the Head of Research and Science Communication at the Institute of Immunology, Invited Assistant at the Faculty of Medicine and Director of the Immunology and Oncology Laboratory of the Center for Neuroscience and Cell Biology, University of Coimbra (Portugal).

PRS developed his work on Immunogenetics under the supervision of Professor Gottfried Mauff at Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine, University of Cologne, Germany. He worked on Transplantation Immunobiology as Head of the Functional Genomics Laboratory at the Center for Histocompatibility of the Centre (Coimbra, Portugal).

PRS was Chair of the Education Committee of the European Federation for Immunogenetics (EFI), Board Member of the European Complement Network (ECN) and Vice-President of the Portuguese Society for Immunology (SPI). Currently, PRS is the President of the Supervisory Board of SPI (2024-2027).

He is Founder and Coordinator of the Portuguese Group of Immuno-Oncology (gpI-O), a joint working group of the Portuguese Society for Oncology (SPO) and the Portuguese Society for Immunology (SPI).

 

PRS is an Editorial Board Member of Discover Immunity, an Associate Editor for Cancer Immunity and Immunotherapy at Frontiers in Immunology and  Frontiers in Oncology; an Associate Editor for Immunogenetics at Frontiers in Genetics; and an Associate Editor for Aging and the Immune System at Frontiers in Aging.

ORCID: 0000-0001-7519-1620
ResearchID: M-3175-2013
Loop profile: 55546
Ciência ID: 4311-1E7F-9AA8

VISION

Our studies are primarily concerned with the signal integration and function-switch of Innate Lymphoid Cells (ILC)​, particularly natural killer (NK) cells.

 

Currently, research on immune monitoring and immunological modulation for cancer therapy is focused on the dynamic growth of innate immune cells and the functional tuning of cell receptors in malignant diseases.

 

Our main objective is to develop and apply innate cell-based immunotherapy to human cancer cells in a therapeutic setting.

 

Leaping forward translational immunology

 

"No one understands the wonders that the immune system can perform better than immunologists, so translation now represents not only an opportunity but also a mandate for immunologists."

 

Drew M Pardoll

Johns Hopkins Univ. School of Medicine, USA.

 

EDITORIAL CONTRIBUTIONS

 

Frontiers in Immunology

Frontiers in Oncology

 

Special Issue
​"Peripheral Blood-Based Biomarkers for Immune Monitoring of Cancer and Cancer Therapy​"

Guest Editors

Paulo Rodrigues Santos, José Manuel Casanova & Raquel Tarazona

More info

 

International Journal of Molecular Sciences

 

Special Issue
​"Innate and Innate-like Lymphoid Cells: New Populations and Old Tricks​"

Guest Editor

Paulo Rodrigues Santos

More info

 

Frontiers in Aging

 

Special Issue
​"Rising Stars in Aging and the Immune System 2023/2024​"

Guest Editors

Paulo Rodrigues Santos, Beatriz Martín-Antonio

 

More info

LAST PUBLICATIONS

 

Original paper
Almeida JS, Sousa LM, Fortes-Andrade TC, Alves V, Martinho A, Rodrigues J, Fonseca R, Freitas-Tavares P, Santos-Rosa M, Casanova JM, Rodrigues-Santos. Peripheral Immune Profiling of Soft Tissue Sarcoma: Perspectives for Disease Monitoring.

Front Immunol 2024. 
Impact factor: 5,7 Q1 (Immunology)

 

Original paper
Domingues N, Catarino S, Cristovao B, Rodrigues-Santos P, Aasen T, Korolchuk VI, Gonçalves T, Milosevic I, Raimundo N. Girão H. Connexin43 promotes exocytosis of damaged lysosomes through actin remodelling. EMBO J 2024. Published online July 23, 2024. doi:10.1038/s44318-024-00177-3.
Impact factor: 12.5 Q1 (Immunology and Microbiology)

 

Book Chapter

Sousa LM, Tralhão JG, Ferreira M, Rodrigues Santos P. Innate Lymphoid Cells in Cancer Immunobiology and Immunotherapy. In Cancer Research: An Interdisciplinary Approach, Ed. Nima Rezaei. Springer Nature, 2024. doi.org/10.1007/16833_2024_368

 

Review paper
Oliveira I, Rodrigues-Santos P, Ferreira L, Pires das Neves R. Synthetic and biological nanoparticles for cancer immunotherapy. Biomater Sci 2024 (in revision).
Impact factor: 6.6 (Q1 Biomaterials Engineering)

 

SAVE THE DATE

 

gpI-O
2nd Immuno-Oncology

SPO/SPI School & Joint Meeting

 

The program will feature an online session with the “SPO/SPI Immuno-Oncology School." on October 18th.
The second day will bring together state-of-the-art clinical and scientific discussions on current topics with presentations from distinguished speakers.

​October 18, 2024. Online

​October 19, 2024. Conímbriga, Portugal.
More info

Get social